Wockhardt Q1 net profit falls 94 pc on plant bans

Tags: Companies
Generic drugmaker Wockhardt Ltd on Tuesday said its quarterly net profit plunged 94 percent, as US Food and Drug Administration bans on its manufacturing plants continued to take a toll.

Wockhardt's April-June net profit was 199.5 million rupees($3.26 million), compared with 3.23 billion rupees a year earlier.

Net sales slumped 27 percent to 9.91 billion rupees.

The United States is Wockhardt's biggest market and the FDA has banned the import of generic drugs from two of the company's plants in India, citing quality lapses in the manufacturing process.

In May, the company said the FDA had also expressed concerns over production processes at its Chicago-based Morton Grove Pharmaceuticals unit, which accounts for more than 50 percent of Wockhardt's sales in the United States.

Wockhardt shares fell 5 percent to 674 rupees by 0627 GMT on Nifty that was up 0.54 percent.

EDITORIAL OF THE DAY

  • Insurance regulator must ban differential pricing and exemptions on health covers

    To reduce their overall losses, non-life insurance companies have been increasing the health insurance premium they charge retail customers, both at t

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Arun Kumar Jain

Reframe mindset to achieve excellence

Niels Bohr, the famous quantum physicist on­ce said, “The opposite ...

Kuruvilla Pandikattu

More real than the reality

Virtual reality (VR), a te­chnology that offers an un­imaginably altered ...

Dharmendra Khandal

Urbanisation is costing us our wildlife

The road transport and highways minister Nitin Gadkari aims to ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture